American Cannabis Company Inc (OTCMKTS:AMMJ) Client Base Expands

American Cannabis Company Inc (OTCMKTS:AMMJ)

American Cannabis Company Inc (OTCMKTS:AMMJ) rallied 10.87% in Wednesday’s trading session as investors reacted to new contract deals that the company has signed in pursuit of revenue opportunities in the cannabis business. The company has inked deals in Arkansas and California as it continues to expand its footprint in the multibillion industry.

Shares of American Cannabis Company Inc (OTCMKTS:AMMJ) have been on an impressive run ever since they tanked to this year’s lows of $0.36 a share in June. The stock is currently trading at the higher end of its $0.67 – $0.82 a share range and faces resistance around $1 a share.

American Cannabis Company Inc (OTCMKTS:AMMJ)
One month stock price chart for AMMJ

American Cannabis Company Inc (OTCMKTS:AMMJ), along with its subsidiaries, provides consulting services and solutions to businesses in the legal cannabis business in the U.S and Canada. Some of the services that the company offers include commercial cannabis business planning, cannabis business license application, and cultivation build out oversight.

The business-to-business consulting solutions provider also owns a portfolio of branded products that include, The Satchel, The Cultivation Cube, and The High-Density Cultivation System.

Consulting Deals

The company is fresh from securing a new client in the fast growing California cannabis industry. The client is in the process of acquiring licenses needed to dispense medical cannabis in the state. American Cannabis Company Inc (OTCMKTS:AMMJ) has been tasked with the responsibility of coming up with complete operational planning activities for a retail location.

The California client has also asked American Cannabis to provide facility staffing solutions, operational workflow procedures and remote operational monitoring systems, pending the approval of the licenses.

“This state, while deeper than most states in its cannabis industry history and tenure, continues to present vast amounts of opportunity within the marketplace. As a company, ACC is actively seeking to align itself with strong clients who have an understanding of what it takes to achieve success,” said CEO, Terry Buffalo.

In addition to the new client in California, the consulting solutions provider has secured a third client in the state of Arkansas. American Cannabis Company Inc (OTCMKTS:AMMJ) will furnish the new client with a robust financial pro-forma modeling while also helping him develop a custom business plan and conceptual design work.

American Cannabis Company Inc. (OTCMKTS:AMMJ) plans to leverage the new deals to secure additional revenue streams through long-term consulting agreements.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $AMMJ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

PAO GROUP INC COM USD0.001 (OTCMKTS:PAOG) Rallies

PAO GROUP INC COM USD0.001 (OTCMKTS:PAOG)

Shares of PAO GROUP INC COM USD0.001 (OTCMKTS:PAOG) were up by 3.64% in Monday’s trading session after the company reported positive cash flows for the second quarter. The stock also continues to ride high after the physician practice management company reported revenue growth.

Quarterly Earnings

Formerly known as New Wave Holdings, PAO GROUP INC COM USD0.001 (OTCMKTS:PAOG) is a management company focused on legal cannabis for chronic pain treatment. The company generated revenues of $165,633 for the three months ended June 30, 2017, compared to zero revenues for the corresponding period last year. Revenue for the six months ended June 30, 2017, totaled $171,260 representing 100% year over year growth.

Net loss for the six months dropped to (-$62,297) down from highs of $107, 741 posted last year. Pao Group’s cash and cash equivalent as of the end of June 30, 2017, stood at $174,434 compared to $7,103 as of June 30, 2016.

In a bid to build up on second quarter performance, PAO GROUP INC COM USD0.001 (OTCMKTS:PAOG) has opened a new Alternative Medicine Centers of America outlet in Parma/Cleveland for booking appointments. The company also plans to open additional locations in Columbus and AKRON-Canton Ohio.

Expansion Drive

The company’s directors are currently conducting due diligence on opportunities in other states, where the company plans to expand its footprint. Some of the markets that the company is closely eyeing include California, Los Angeles, and Michigan.

“We are well ahead of our timeline goals in Ohio which has allowed us to be equally assertive with efforts in Florida. [..] E are also looking at additional sites for locations in Central and South Florida,” said CEO Robert Weber

Dayton’s location will act as an in-house psychiatrist facility for offering proper diagnosis for PTSD in line with the company’s mission of treating with compassionate care. PAO GROUP INC COM USD0.001 (OTCMKTS:PAOG) plans to provide a comprehensive package of therapies, treatments and products as well as health education in the new facilities.

Clinic offering at the facilities will include proper use of marijuana to treat chronic pain as well as terminally ill patients. Massage therapy, as well as anti-ageing treatments and hormone replacement therapy, will also come in handy.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PAOG and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

MagneGas Corporation (NASDAQ:MNGA) Awarded Ground Breaking Patent

MagneGas Corporation (NASDAQ:MNGA)

Shares of MagneGas Corporation (NASDAQ:MNGA) dropped 6.68% even as the company announced that the U.S. Patent and Trademark Office (USPTO) had granted it a ground breaking patent.  The ‘MagneCule’ patent details the use of energy in a manner that changes the shape of affected molecules – thereby changing their bonding mechanism.

NASDAQ:MNGA
One Month Daily Candlebar Graph for $MNGA

Ground Breaking Patent

According to the MagneGas Corporation (NASDAQ:MNGA) a change in the bonding mechanism could lead to a more effective energy footprint – particularly in hydrogen molecules. The patented MagneCule theory according to chief executive officer Ermanno Santilli has numerous applications in the energy, transportation, and space industries.

“We believe that as these industries are under pressure to innovate, our newly released patented technology places us in an ideal position to provide value added innovation to numerous applications,” said Mr. Santilli

MagneGas Corporation (NASDAQ:MNGA) is planning to explore a low-cost proof-of-concept development project, and licensing opportunities, to validate the new technology. Chief Financial Officer Scott Mahoney expects development projects to help expand the company’s footprint in the target industries.

MagneGas Corporation (NASDAQ:MNGA) is an alternative energy company focused on the production of hydrogen-based fuel through gasification of carbon rich liquids. The company boasts of a patented process that converts liquid wastes into MagneGas fuels. The company’s leading product, MagneGas2, has already proved to be cleaner, more productive, and faster than other alternatives in the market.

MagneGas2 Marketing Drive

The company recently confirmed the appointment of a senior supply chain industry executive who could attract up to 80 distinct automotive fabrication and manufacturing facility relationships. MagneGas Corporation (NASDAQ:MNGA) expects the relationships to help drive sales for MagneGas2.

Some of the facilities have an annual spend of between $75,000 and $100,000 on alternative sources of energy. The hire, according to the CEO, represents a significant step in the company’s push to penetrate the global automotive industry.

Last month, MagneGas Corporation (NASDAQ:MNGA) received a grant of $431,874 from the US Department of Agriculture, the grant is to be used to accelerate the commercialization of MagneGas Plasma Arc Venturi stabilization system.  The company plans to carry out a number of commercialization projects in the U.S, Europe, Latin America and Asia.

“This funding provides a significant source of non-dilutive capital for further investment in our sterilization business segment,” said Mr. Mahoney.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $MNGA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: James Marion is a University of Houston student studying Business with a concentration in Finance. James has interned with several investment professionals and hopes to pursue a career as a professional stock analyst after graduation.

Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) Unveils Cannabis-Cancer Genetics Lab

Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX)

Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) jumped 8.76% in Monday’s trading session after announcing the establishment of a human cannabis-cancer genetics lab that will offer personalized cancer diagnostics. The lab will develop diagnostic tools based on one’s human genome as well as tumor genetics and cannabinoids.

OTCMKTS:CNBX
Daily Candle Bar Graph $CNBX

The company has appointed Dr. Moran Grinberg to lead the genetic research team in the wake of the establishment of the cannabis-cancer genetics lab. Moran joins the company with vast experience in clinical pharmacology.

“Our mission is to commercialize a wide range of diagnostic tools that incorporate novel technologies to retrieve better outcomes of cannabinoid treatments. Understanding the genetics of cancer-cannabinoids relations complements our CTC cell count and drug sensitivity capabilities,” said Eyal Ballan, Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) CTO.

Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) is a biotechnology company focused on the development and licensing of cannabinoid-based treatments and therapies. The company’s research and development operations are based in Israel and are dedicated to the development of Personalized Anti-Cancer and Palliative treatments. Cannabics utilizes advanced screening systems and personalized bioinformatics tools to come up with personalized natural therapies for cancer.

SIMFO GmbH Collaboration

The company is fresh from signing a collaboration agreement with SIMFO GmbH – a world leader in cancer diagnostics. Under the terms of the agreement, Cannabics Pharmaceuticals Inc. (OTCMKTS:CNBX) is to become the exclusive global provider of the SIMFO’s CTC diagnostics. Mr. Ballan expects the collaboration to pave way for the development of effective natural anticancer therapy.

The diagnostics in question include a count of circulating tumor cells as well as drug sensitivity tests of different cannabinoids. SIMFO is currently utilizing Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) cannabinoid formulations as part of preclinical studies on cannabinoid antitumor activity and drug development.

Positive CTC Test Results

Last month, Cannabics received positive results from screening necrosis from cancer patients treated with its cannabinoids CBD and CBDA. The topline results affirm the company’s previously calculated data with regards to anti-tumor activity. The study results also indicate that Cannabics Pharmaceuticals Inc (OTCMKTS:CNBX) proprietary technology can be relied upon in providing supportive data for personalized treatments.

“The screening of CTCs treated with specific cannabinoids and CTC cell count of patients treated with cannabinoids produces an invaluable body of data in our search for effective anti-tumor treatment,” said Mr. Ballan.

Cannabics Pharmaceuticals Inc. (OTCMKTS:CNBX) recently raised $3 million that it plans to use to accelerate the development of a platform for personalized treatments with cannabis. The company plans to expand collaborations with biotech companies in a bid to harness new technologies for examining anti-tumor properties in its R&D lab.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CNBX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Monica has an undergraduate degree in Accounting and an MBA she earned – with Honors. She has six years of experience in the financial markets and has been an analyst for the past two years.

American Cannabis Company Inc (OTCMKTS:AMMJ) Inks New Deals As Expansion Drive Gathers Pace

American Cannabis Company Inc (OTCMKTS:AMMJ)

American Cannabis Company Inc (OTCMKTS:AMMJ) is expanding its footprint in the state of Louisiana having announced the signing of an agreement with CB Medical. The signing of the agreement comes barely a few weeks after the company confirmed the signing of a similar agreement with its first client in Alberta, Canada.

CB Medical-American Cannabis Deal

CB Medical, one of the applicants for the Louisiana State University medical marijuana program, is the latest kid on the block to bet big on the fast growing cannabis business. The company is relying on American Cannabis Company Inc (OTCMKTS:AMMJ) as part of the agreement to assist it in the designing of a medical marijuana program for patients.

The medical marijuana program under consideration will consist of a production facility – likely in Baton Rouge. Custom built for medical marijuana production, the facility will come with an indoor cultivation center as well as a formulation lab.

According to CB Medical Chairman, Kenneth PeregoOnce, the facility will be used to highlight American Cannabis Company Inc (OTCMKTS:AMMJ) proprietary cultivation methods .

“We are excited to have American Cannabis Company as our long-term partner for the LSU project. We selected them as our [cannabis] consultant because we believe that they are the best at what they do in the industry,” said Mr. Perego in a statement.

American Cannabis Expansion Drive

In addition to CB Medical agreement, American Cannabis Company Inc (OTCMKTS:AMMJ) will be working with its new Canadian client to lay the foundation for a license acquisition as well as develop a business plan. The company will also provide the new client with conceptual design work for a cultivation and manufacturing facility.

Separately five of American Cannabis Company Inc (OTCMKTS:AMMJ) clients in Pennsylvania have submitted the necessary application materials and supporting documents for acquiring medical marijuana licenses. Two of the clients are seeking permission to be allowed to dispense medical cannabis while one client has applied a license for the cultivation of medical marijuana. The remaining two clients are applying for a dual license that will allow them to cultivate and dispense marijuana products at the same time.

American Cannabis Company Inc (OTCMKTS:AMMJ) stock was down by 13.99% in Wednesday trading session ending the day at lows of $0.470 a share.

I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 96 hours. All information, or data, is provided with no guarantees of accuracy.

About the author: Monica Gray has an undergraduate degree in Accounting and an MBA – earned with Honors. She has six years of experience in the financial markets and has been a securities analyst for the past two years.